We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel RT-PCR Test Enables Early Detection of Parkinson’s Disease

By LabMedica International staff writers
Posted on 29 Sep 2023

Parkinson's disease (PD) is a neurological disorder with no known definitive cause, although it is thought that both genetics and environmental factors play a role. More...

There is currently no cure for the disease. When patients begin to show typical signs of PD, a significant loss of dopamine-producing cells has already occurred, making it difficult to halt further brain decline. As the disease advances, problems with movement and speech arise, affecting the individual's independence. For these reasons, genetic testing becomes vital for assessing an individual's risk and for early detection. Identifying specific genetic mutations linked to PD not only helps people make educated healthcare choices but also guides researchers in developing targeted treatments. Understanding these genetic factors can further contribute to personalized treatment strategies, improving patient care.

In the search for early detection methods for PD, accurately identifying the condition has proven to be challenging. Anbio Biotechnology (Frankfurt, Germany) has developed a promising approach using real-time polymerase chain reaction (RT-PCR) technology for early PD detection. Studies have found that early-onset PD is commonly associated with mutations in the GBA and LRRK2 genes. Among these mutations, L444P, G2385R, and R1628P are notably prevalent. To address this, Anbio has introduced its GBA L444P/LRRK2 R1628P/LRRK2 G2385R Gene Mutations Polymorphism Test Kit. This RT-PCR assay is specifically designed to rapidly and accurately identify these three key genetic polymorphisms in the GBA and LRRK2 genes.

The kit employs a highly specialized Taq enzyme and fluorescent probes to enhance detection specificity. Quality control is maintained through the use of internal and multiple positive controls, reducing the chances of false negatives and positives. The test can identify these three specific GBA and LRRK2 genetic polymorphisms in as little as 117 minutes. The procedure is straightforward, and the test results are easy to understand, objective, and reliable. When it comes to accuracy, sensitivity, and specificity, the kit outperforms other similar products available on the market. The findings generated by Anbio's test kit are significant not only for understanding the mechanisms behind PD but also for shaping effective treatment strategies.

Related Links:
Anbio Biotechnology 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.